経カテーテル僧帽弁移植(TMVI):医療機器パイプライン分析

◆英語タイトル:Transcatheter Mitral Valve Implantation (TMVI) - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0167
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:114
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD8,000 ⇒換算¥848,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD12,000 ⇒換算¥1,272,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Transcatheter Mitral Valve Implantation (TMVI) – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Transcatheter Mitral Valve Implantation (TMVI) – Medical Devices Pipeline Assessment, 2019″ provides an overview of Transcatheter Mitral Valve Implantation (TMVI) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Mitral Valve Implantation (TMVI) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Transcatheter Mitral Valve Implantation (TMVI) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Transcatheter Mitral Valve Implantation (TMVI) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Transcatheter Mitral Valve Implantation (TMVI) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 4
1.2 List of Figures 7
2 Introduction 8
2.1 Transcatheter Mitral Valve Implantation (TMVI) Overview 8
3 Products under Development 9
3.1 Transcatheter Mitral Valve Implantation (TMVI) – Pipeline Products by Stage of Development 9
3.2 Transcatheter Mitral Valve Implantation (TMVI) – Pipeline Products by Territory 10
3.3 Transcatheter Mitral Valve Implantation (TMVI) – Pipeline Products by Regulatory Path 11
3.4 Transcatheter Mitral Valve Implantation (TMVI) – Pipeline Products by Estimated Approval Date 12
3.5 Transcatheter Mitral Valve Implantation (TMVI) – Ongoing Clinical Trials 13
4 Transcatheter Mitral Valve Implantation (TMVI) – Pipeline Products under Development by Companies 14
4.1 Transcatheter Mitral Valve Implantation (TMVI) Companies – Pipeline Products by Stage of Development 14
4.2 Transcatheter Mitral Valve Implantation (TMVI) – Pipeline Products by Stage of Development 15
5 Transcatheter Mitral Valve Implantation (TMVI) Companies and Product Overview 17
5.1 4C Medical Technologies Inc Company Overview 17
5.1.1 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Annulon Company Overview 20
5.2.1 Annulon Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 CardioMech AS Company Overview 21
5.3.1 CardioMech AS Pipeline Products & Ongoing Clinical Trials Overview 21
5.4 Cardiovalve Ltd Company Overview 22
5.4.1 Cardiovalve Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
5.5 Cephea Valve Technologies, Inc. Company Overview 26
5.5.1 Cephea Valve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 26
5.6 Colibri Heart Valve LLC Company Overview 29
5.6.1 Colibri Heart Valve LLC Pipeline Products & Ongoing Clinical Trials Overview 29
5.7 Daidalos Solutions BV Company Overview 30
5.7.1 Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 30
5.8 Direct Flow Medical Inc (Inactive) Company Overview 31
5.8.1 Direct Flow Medical Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31
5.9 Dura LLC Company Overview 32
5.9.1 Dura LLC Pipeline Products & Ongoing Clinical Trials Overview 32
5.10 Edwards Lifesciences Corp Company Overview 33
5.10.1 Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
5.11 Emory University Company Overview 46
5.11.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 46
5.12 Foldax Inc Company Overview 47
5.12.1 Foldax Inc Pipeline Products & Ongoing Clinical Trials Overview 47
5.13 HighLife SAS Company Overview 48
5.13.1 HighLife SAS Pipeline Products & Ongoing Clinical Trials Overview 48
5.14 LivaNova PLC Company Overview 51
5.14.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 51
5.15 Medtronic plc Company Overview 55
5.15.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 55
5.16 Micro Interventional Devices, Inc. Company Overview 60
5.16.1 Micro Interventional Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.17 MitrAssist Ltd. Company Overview 61
5.17.1 MitrAssist Ltd. Pipeline Products & Ongoing Clinical Trials Overview 61
5.18 MValve Technologies Ltd. Company Overview 62
5.18.1 MValve Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 62
5.19 NaviGate Cardiac Structures, Inc. Company Overview 65
5.19.1 NaviGate Cardiac Structures, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65
5.20 Neovasc Inc Company Overview 68
5.20.1 Neovasc Inc Pipeline Products & Ongoing Clinical Trials Overview 68
5.21 Polares Medical SA Company Overview 72
5.21.1 Polares Medical SA Pipeline Products & Ongoing Clinical Trials Overview 72
5.22 Sino Medical Sciences Technology Inc Company Overview 73
5.22.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.23 Trinity College Dublin Company Overview 74
5.23.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 74
5.24 University College London Company Overview 75
5.24.1 University College London Pipeline Products & Ongoing Clinical Trials Overview 75
5.25 Venus MedTech Company Overview 76
5.25.1 Venus MedTech Pipeline Products & Ongoing Clinical Trials Overview 76
6 Transcatheter Mitral Valve Implantation (TMVI)- Recent Developments 77
6.1 Nov 21, 2019: LivaNova to revamp heart valve division to affect 150 jobs 77
6.2 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 77
6.3 Oct 23, 2019: Edwards Lifesciences reports third quarter results 80
6.4 Oct 21, 2019: Sean Salmon named executive vice president and group president of Medtronic Diabetes 83
6.5 Oct 15, 2019: Neovasc announces Notice of US Patent Granted for TiaraTranscatheter Device for treatment of severe mitral regurgitation 84
6.6 Oct 10, 2019: CINDE announces Edwards Lifesciences invests $100 million to expand its operations in Costa Rica 84
6.7 Sep 30, 2019: AltaValve, 4C Medical’s Novel Transcatheter Mitral Regurgitation Device Highlighted at TCT 2019 86
6.8 Sep 27, 2019: Medtronic announces early feasibility Trial for Intrepid Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal approach 86
6.9 Aug 28, 2019: Medtronic announces planned leadership succession 87
6.10 Aug 20, 2019: Medtronic reports first quarter financial results for 2019 89
6.11 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 91
6.12 Jul 23, 2019: Edwards Lifesciences reports second quarter results for the year 2019 92
6.13 Jun 17, 2019: Tiara featured in presentation at 11th Annual TVT 2019 English 94
6.14 May 23, 2019: Medtronic announces fiscal year and fourth quarter 2019 financial results 94
6.15 May 22, 2019: Edwards announces milestones for Transcatheter Mitral Program 97
6.16 May 20, 2019: Novel technique reduces obstruction risk in heart valve replacement 98
6.17 Apr 23, 2019: Edwards Lifesciences announces first quarter results 99
6.18 Apr 17, 2019: Neovasc announces resolution of last remaining active litigation 100
6.19 Mar 25, 2019: Medtronic launches Medtech Innovation Accelerator in Shanghai 101
6.20 Mar 21, 2019: Neovasc wins German court appeal; announces german court’s Decision to dismiss CardiAQ’s claim to co-inventorship of a European patent for Tiara 102
6.21 Mar 04, 2019: Neovasc’s Tiara Mitral Valve replacement technology featured in update presentation at the CRT 2019 Meeting 103
6.22 Feb 25, 2019: 4C Medical’s novel mitral regurgitation therapy to be highlighted at CRT 2019 Meeting 104
6.23 Feb 21, 2019: Edwards Lifesciences secures CE-Mark for Pascal system 104
6.24 Feb 21, 2019: Neovasc celebrates 5-year anniversary of Tiara patient as the longest surviving transcatheter mitral valve replacement in the world 105
6.25 Feb 20, 2019: Micro Interventional Devices reaches settlement agreement with Neovasc 106
6.26 Jan 31, 2019: Edwards Lifesciences reports financial results for the quarter ended December 31, 2018 106
6.27 Jan 29, 2019: Neovasc receives approval to proceed with phase 2 of TIARA-II study from clinical regulators in Germany and the UK 108
6.28 Jan 22, 2019: Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences 109
6.29 Jan 15, 2019: Boston Scientific, Edwards Lifesciences agree to global litigation settlement 109
6.30 Jan 09, 2019: Medtronic Foundation Recognizes 12 Bakken Invitation Honorees for Driving Positive Change in Healthcare 109
7 Appendix 111
7.1 Methodology 111
7.2 About GlobalData 114
7.3 Contact Us 114
7.4 Disclaimer 114

List of Tables
Table 1: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Stage of Development
Table 2: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Territory
Table 3: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Regulatory Path
Table 4: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Estimated Approval Date
Table 5: Transcatheter Mitral Valve Implantation (TMVI) - Ongoing Clinical Trials
Table 6: Transcatheter Mitral Valve Implantation (TMVI) Companies - Pipeline Products by Stage of Development
Table 7: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Stage of Development
Table 8: 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: AltaValve - Product Status
Table 10: AltaValve - Product Description
Table 11: 4C Medical Technologies Inc - Ongoing Clinical Trials Overview
Table 12: AltaValve - AltaValve Early Feasibility Study Protocol
Table 13: Annulon Pipeline Products & Ongoing Clinical Trials Overview
Table 14: Mitral Valve Replacement Device - Product Status
Table 15: Mitral Valve Replacement Device - Product Description
Table 16: CardioMech AS Pipeline Products & Ongoing Clinical Trials Overview
Table 17: Transcatheter Mitral Valve Repair System - Product Status
Table 18: Transcatheter Mitral Valve Repair System - Product Description
Table 19: Cardiovalve Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Valtech Cardiovalve - Product Status
Table 21: Valtech Cardiovalve - Product Description
Table 22: Cardiovalve Ltd - Ongoing Clinical Trials Overview
Table 23: Valtech Cardiovalve - Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk with Severe Mitral Regurgitation
Table 24: Valtech Cardiovalve - Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation
Table 25: Valtech Cardiovalve - Early Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System
Table 26: Valtech Cardiovalve - European Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System (AHEAD Study)
Table 27: Cephea Valve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Mitral Valve Replacement Device - Product Status
Table 29: Mitral Valve Replacement Device - Product Description
Table 30: Cephea Valve Technologies, Inc. - Ongoing Clinical Trials Overview
Table 31: Mitral Valve Replacement Device - Cephea Mitral Valve and Transseptal Delivery System FIH
Table 32: Colibri Heart Valve LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Mitral Valve - Product Status
Table 34: Mitral Valve - Product Description
Table 35: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Sutureless Trans-Catheter Mitral Valve Replacement (TMVR) - Product Status
Table 37: Sutureless Trans-Catheter Mitral Valve Replacement (TMVR) - Product Description
Table 38: Direct Flow Medical Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 39: Direct Flow Medical Transcatheter Mitral Valve - Product Status
Table 40: Direct Flow Medical Transcatheter Mitral Valve - Product Description
Table 41: Dura LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 42: Sutra TMVR System - Product Status
Table 43: Sutra TMVR System - Product Description
Table 44: Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 45: CardiAQ Mitral Valve - Product Status
Table 46: CardiAQ Mitral Valve - Product Description
Table 47: EVOQUE Mitral Valve Replacement Device - Product Status
Table 48: EVOQUE Mitral Valve Replacement Device - Product Description
Table 49: FORTIS Mitral Transcatheter Heart Valve - Product Status
Table 50: FORTIS Mitral Transcatheter Heart Valve - Product Description
Table 51: PASCAL Transcatheter Mitral Valve Repair System - Product Status
Table 52: PASCAL Transcatheter Mitral Valve Repair System - Product Description
Table 53: Sapien 3 Heart Valve - Mitral Annular Calcification - Product Status
Table 54: Sapien 3 Heart Valve - Mitral Annular Calcification - Product Description
Table 55: SAPIEN M3 - Product Status
Table 56: SAPIEN M3 - Product Description
Table 57: Second Generation Transapical Transcatheter Mitral Valve - Product Status
Table 58: Second Generation Transapical Transcatheter Mitral Valve - Product Description
Table 59: Edwards Lifesciences Corp - Ongoing Clinical Trials Overview
Table 60: FORTIS Mitral Transcatheter Heart Valve - Early Feasibility Study of the Edwards EVOQUE Transcatheter Mitral Valve Replacement System For the Treatment of Moderate to Severe Mitral Regurgitation
Table 61: CardiAQ Mitral Valve - Early Feasibility Study of the Edwards EVOQUE Transcatheter Mitral Valve Replacement System For the Treatment of Moderate to Severe Mitral Regurgitation
Table 62: Sapien 3 Heart Valve - Mitral Annular Calcification - Surgical Implantation of Transcatheter valve in Native Mitral Annular Calcification (SITRAL) Study
Table 63: Sapien 3 Heart Valve - Mitral Annular Calcification - The Safety and Feasibility of the SAPIEN XT Transcatheter Heart Valve with Novaflex and Ascendra Delivery Systems and SAPIEN 3 with Commander Delivery System in Patients with Symptomatic Severe Calcific Mitral Valve Disease with Severe Mitral Annular Calcification and Patients with Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery
Table 64: PASCAL Transcatheter Mitral Valve Repair System - CE Mark Study of PASCAL Transcatheter Mitral Valve Repair System

List of Figures
Figure 1: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Stage of Development
Figure 2: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Territory
Figure 3: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Regulatory Path
Figure 4: Transcatheter Mitral Valve Implantation (TMVI) - Pipeline Products by Estimated Approval Date
Figure 5: Transcatheter Mitral Valve Implantation (TMVI) - Ongoing Clinical Trials

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[経カテーテル僧帽弁移植(TMVI):医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆